News Releases

Webcast Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast
October 14, 2014
8:30 AM ET

All Releases
View Summary Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results:
Jan 20, 2015
PDF 72.5 KB Add to Briefcase
View Summary FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia
Jan 19, 2015
PDF 83.2 KB Add to Briefcase
View Summary Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
Jan 16, 2015
PDF 18.5 KB Add to Briefcase
View Summary Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution
Jan 15, 2015
PDF 12.4 KB Add to Briefcase
View Summary Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
Jan 6, 2015
PDF 17.6 KB Add to Briefcase
View Summary Johnson & Johnson Announces Quarterly Dividend for First Quarter 2015
Jan 5, 2015
PDF 6.8 KB Add to Briefcase
View Summary Johnson & Johnson to Participate in 33rd Annual JP Morgan Health Care Conference
Dec 30, 2014
PDF 7.0 KB Add to Briefcase
View Summary Janssen Announces Collaboration with Gilead to Develop Prezista®-Based Single-Tablet Regimen for the Treatment of People Living with HIV
Dec 29, 2014
PDF 19.3 KB Add to Briefcase
View Summary Janssen Receives Positive CHMP Opinion Recommending VELCADE® (bortezomib) for use in Mantle Cell Lymphoma
Dec 19, 2014
PDF 64.3 KB Add to Briefcase
View Summary Johnson & Johnson to Host Fourth-Quarter/Full-Year 2014 Investor Conference Call on Results
Dec 17, 2014
PDF 8.8 KB Add to Briefcase
View Summary IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation
Dec 8, 2014
PDF 69.5 KB Add to Briefcase
View Summary IMBRUVICA® (ibrutinib) Long-term Follow-up Data in Patients Living with Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years
Dec 8, 2014
PDF 70.5 KB Add to Briefcase
View Summary Animas® Vibe Insulin Pump and Continuous Glucose Monitoring System Receives FDA Approval
Dec 1, 2014
PDF 13.1 KB Add to Briefcase
View Summary Application Submitted To The EMA To Expand The Therapeutic Indication For IMBRUVICA® (ibrutinib) To Include Treatment Of Waldenström's Macroglobulinemia
Dec 1, 2014
PDF 18.4 KB Add to Briefcase
View Summary European Commission Approves REZOLSTA®▼, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat
Nov 25, 2014
PDF 53.7 KB Add to Briefcase
View Summary Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Nov 24, 2014
PDF 19.1 KB Add to Briefcase
View Summary Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate
Nov 19, 2014
PDF 20.8 KB Add to Briefcase
View Summary Health Canada Approves IMBRUVICA by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia
Nov 19, 2014
PDF 13.9 KB Add to Briefcase
View Summary Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care
Nov 18, 2014
PDF 24.8 KB Add to Briefcase
View Summary U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder
Nov 13, 2014
PDF 69.5 KB Add to Briefcase

= add release to Briefcase